# BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.

> **NCT00668057** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 624 (actual)

## Conditions studied

- Erectile Dysfunction

## Interventions

- **DRUG:** Levitra (Vardenafil, BAY38-9456)
- **DRUG:** Levitra (Vardenafil, BAY38-9456)
- **DRUG:** Levitra (Vardenafil, BAY38-9456)
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00668057
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** 624 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00668057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00668057, "BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00668057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*